A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma

NCT01949818 Phase 4 UNKNOWN

The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.

Details

Lead sponsor	Mingzhi Zhang
Phase	Phase 4
Status	UNKNOWN
Enrolment	120
Start date	2012-09
Completion	2018-09

Conditions

• Diffuse Large B Cell Lymphoma

Interventions

• Yangzhengxiaoji capsule combined with CHOP regimen
• CHOP regimen

Primary outcomes

• Progression-free survival — up to end of follow-up-phase (approximately 24 months)

Countries

China